-
Patient Reported Outcomes in BRUIN CLL-321: A Phase 3 Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Mar 10, 2025, 14:00 PM -
Use of Clinical Outcome Assessments in Specialty Drug Coverage Policies
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness of Olanzapine for Cancer Cachexia Management
Mar 10, 2025, 14:00 PM -
Tremor Symptoms and Associated Activities of Daily Living Impacts in Essential Tremor: A Qualitative Concept Elicitation and Mapping Study
Mar 10, 2025, 14:00 PM -
The HER2-TRENDS StudyHR Positive - HER2 Negative Metastatic Breast Cancer (mBC) Treatment Patterns and Clinical Outcomes in Canada
Mar 10, 2025, 14:00 PM -
Relationships Between ICER Clinical Evidence Ratings and FDA Approval Decisions
Mar 10, 2025, 14:00 PM -
Costs of Care for Patients With Triple Negative Metastatic Breast Cancer: A Retrospective US Claims Data Study
Mar 10, 2025, 14:00 PM -
The Unseen Progress: How PROs May Overlook the Value of Slowing Degenerative Decline
Mar 10, 2025, 14:00 PM -
Adjusted Comparison of Amivantamab in Combination With Carboplatin Plus Pemetrexed From the PAPILLON Study Versus US Real-World Frontline Treatments in Patients With Advanced NSCLC Harboring EFGR Exon 20 Insertions
Mar 10, 2025, 14:00 PM -
Systematic Review of Secondary Primary Malignancies (SPMs) in Patients Treated with Chimeric Antigen Receptor T-cell (CAR-T) Therapies
Mar 10, 2025, 14:00 PM -
The Inflation Reduction Act: Evaluating Impact on Medicare Drug Pricing, Innovation, and Access to Therapies
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness of Talazoparib Plus Enzalutamide for HRR-Deficient Metastatic Castration-Resistant Prostate Cancer
Mar 10, 2025, 14:00 PM -
Systematic Literature Review and Network Meta-Analysis of Crovalimab Compared With Eculizumab, Ravulizumab and Best Supportive Care in Paroxysmal Nocturnal Hemoglobinuria
Mar 10, 2025, 14:00 PM -
Addressing Neighborhood-Level Opioid Data Gaps: Development of an Interactive Dashboard for Prescription Trends and Buprenorphine Access in California
Mar 10, 2025, 14:00 PM -
Health Utility Values of Canadian Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Mar 10, 2025, 14:00 PM -
The Evolution of Language in Clinical Outcome Assessments- An Analysis of Source Wording Updates, Translation Updates, and the Need to Periodically Assess the Revelance of Linguistically Validated Translations
Mar 10, 2025, 14:00 PM -
The Role of Social Determinants of Health (SDoH) Data in Improving Risk Predictions
Mar 10, 2025, 14:00 PM -
Advancing Health Equity in Economic Evaluations, With The Distributional Generalized Risk-Adjusted Cost-Effectiveness (DGRACE) Model
Mar 10, 2025, 14:00 PM -
Short- and Longer-Term Healthcare Resource Utilization and Related Costs of Stroke in the Brazilian Private Market from 2019 to 2023
Mar 10, 2025, 14:00 PM -
The Cost-effectiveness Analysis of Gene Therapy for Severe Hemophilia B Patients in China: A Microsimulation Experiment Study
Mar 10, 2025, 14:00 PM
